Too close to call on the filings — the two names are within a point on our blended read; the better pick depends on which risk profile you prefer.
Cash-generative, deleveraging biopharma growing ~10% at a fair its multiple — but heavy debt and Repatha patent risk cap upside.
Fair-value HIV cash machine: Biktarvy moat extended to 2036 and Yeztugo launching, but flat sales and oncology misses cap upside.
| Metric | AMGN | GILD |
|---|---|---|
| Fundamentals score | 84 | 85 |
| Revenue growth (YoY) | +10.0% | +2.4% |
| Net income growth (YoY) | +88.5% | +1672.9% |
| Net margin | 21.0% | 28.9% |
| Return on equity | 89.1% | 37.5% |
| ROIC (est.) | 11.3% | 16.6% |
| Liabilities / Equity | — | — |
| Piotroski F-score | 6 / 9 | 7 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 18, 2026, 7:11 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 19, 2026, 2:16 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.